Xinnate AB
PrivateLast Round
VC Round
Dec 18, 2025
Total Funding Raised
$1.77M
Company Overview
Xinnate AB operates in Healthcare & Life Sciences and is based in Lund. Its latest recorded funding round was a VC Round in December 2025.
Xinnate AB is a pharmaceutical company that develops novel peptide-based therapies for the treatment of inflammatory skin conditions and wounds.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xinnate AB Comparables
Compare Xinnate AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioMendics | 80% | |
| Aegle Therapeutics Corp | 79% | |
| TWi Biotechnology, Inc. | 78% |
For institutional investors. Book with your work email.
Xinnate AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 18, 2025 | ||||
| VC Round | Jul 1, 2025 | ||||
| Grant | Jul 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xinnate AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| United States Department of Defense | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
CMO speaking at the EB 2026 International Congress.
- Jul 1, 2025
$3.2M round raised.
For institutional investors. Book with your work email.
Xinnate AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xinnate AB's valuation, stock price, and market status.
Is Xinnate AB a public or private company?
Xinnate AB is a private company.
What is the current stock price of Xinnate AB?
Xinnate AB is a private company, so its shares have no public market price. Caplight tracks Xinnate AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xinnate AB worth (valuation)?
Valuation information for Xinnate AB is not publicly available.
Can I buy Xinnate AB stock?
Xinnate AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xinnate AB's last funding round?
Xinnate AB's most recent funding round was VC Round on December 18, 2025.
Who are the main investors in Xinnate AB?
Key investors in Xinnate AB include United States Department of Defense.
Will Xinnate AB IPO soon?
No public IPO plans have been announced for Xinnate AB.
How can I track Xinnate AB secondary market activity?
Caplight tracks bids, offers, and trades in Xinnate AB's shares on secondary markets.